Voya Investment Management LLC Decreases Holdings in Aquestive Therapeutics, Inc. $AQST

Voya Investment Management LLC trimmed its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 14.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,216 shares of the company’s stock after selling 3,485 shares during the period. Voya Investment Management LLC’s holdings in Aquestive Therapeutics were worth $59,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in AQST. Millennium Management LLC grew its holdings in Aquestive Therapeutics by 111.2% during the 4th quarter. Millennium Management LLC now owns 87,227 shares of the company’s stock valued at $311,000 after purchasing an additional 45,926 shares during the last quarter. ProShare Advisors LLC grew its holdings in Aquestive Therapeutics by 79.8% during the 4th quarter. ProShare Advisors LLC now owns 25,232 shares of the company’s stock valued at $90,000 after purchasing an additional 11,200 shares during the last quarter. Two Sigma Investments LP grew its holdings in Aquestive Therapeutics by 31.5% during the 4th quarter. Two Sigma Investments LP now owns 175,952 shares of the company’s stock valued at $626,000 after purchasing an additional 42,160 shares during the last quarter. Two Sigma Advisers LP bought a new position in Aquestive Therapeutics during the 4th quarter valued at about $57,000. Finally, Sugar Maple Asset Management LLC bought a new position in Aquestive Therapeutics during the 1st quarter valued at about $86,000. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Stock Up 5.2%

NASDAQ:AQST opened at $5.88 on Thursday. Aquestive Therapeutics, Inc. has a 52 week low of $2.12 and a 52 week high of $6.43. The firm has a 50 day moving average of $4.46 and a 200 day moving average of $3.55. The stock has a market capitalization of $586.35 million, a price-to-earnings ratio of -8.40 and a beta of 1.77.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The company had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. As a group, analysts expect that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Insiders Place Their Bets

In other Aquestive Therapeutics news, insider Peter E. Boyd sold 15,000 shares of the firm’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $5.30, for a total value of $79,500.00. Following the completion of the transaction, the insider owned 288,323 shares of the company’s stock, valued at approximately $1,528,111.90. This trade represents a 4.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Daniel Barber sold 91,343 shares of the firm’s stock in a transaction on Friday, September 26th. The stock was sold at an average price of $6.03, for a total transaction of $550,798.29. Following the completion of the transaction, the chief executive officer directly owned 923,430 shares of the company’s stock, valued at approximately $5,568,282.90. This represents a 9.00% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 178,923 shares of company stock valued at $1,006,598. Insiders own 8.35% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on AQST shares. Oppenheimer upped their price target on shares of Aquestive Therapeutics from $7.00 to $8.00 and gave the company an “outperform” rating in a report on Monday, September 8th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, June 17th. Lifesci Capital upgraded shares of Aquestive Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 3rd. Finally, Zacks Research upgraded shares of Aquestive Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $10.29.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.